Publicaciones en las que colabora con Jaime Feliu Batlle (12)

2023

  1. Efficacy of second and third lines of treatment in advanced soft tissue sarcomas: a real-world study

    Clinical and Translational Oncology, Vol. 25, Núm. 12, pp. 3519-3526

2022

  1. Antitumoral Effect of Plocabulin in High Grade Serous Ovarian Carcinoma Cell Line Models

    Frontiers in Oncology, Vol. 12

  2. Prognostic implications of tumor-infiltrating T cells in early-stage endometrial cancer

    Modern Pathology, Vol. 35, Núm. 2, pp. 256-265

2021

  1. Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma?

    Clinical and Translational Oncology, Vol. 23, Núm. 3, pp. 536-542

  2. Cancer survivors referred to a long-term survivorship outpatient service within academic medical oncology: descriptive study

    Journal of Cancer Survivorship, Vol. 15, Núm. 6, pp. 811-817

  3. Incidence of venous thromboembolic events in cancer patients receiving immunotherapy: a single-institution experience

    Clinical and Translational Oncology, Vol. 23, Núm. 6, pp. 1245-1252

  4. Motixafortide and pembrolizumab combined to nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic cancer: The COMBAT/ KEYNOTE-202 trial

    Clinical Cancer Research, Vol. 27, Núm. 18, pp. 5020-5027

2020

  1. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

    Nature Medicine, Vol. 26, Núm. 6, pp. 878-885

  2. Prognostic value of neutrophil-to-lymphocyte ratio and other inflammatory markers in patients with high-risk soft tissue sarcomas

    Clinical and Translational Oncology, Vol. 22, Núm. 10, pp. 1849-1856

2018

  1. High-throughput 3-dimensional culture of epithelial ovarian cancer cells as preclinical model of disease

    Oncotarget, Vol. 9, Núm. 31, pp. 21893-21903

2017

  1. Recommendations for SIR-Spheres Y-90 resin microspheres in chemotherapy-refractory/intolerant colorectal liver metastases

    Future Oncology, Vol. 13, Núm. 23, pp. 2065-2082

1991

  1. Antiemetic regimens in outpatients receiving cisplatin and non-cisplatin chemotherapy: A randomized trial comparing high-dose metoclopramide plus methylprednisolone with and without lorazepam

    Acta Oncologica, Vol. 30, Núm. 5, pp. 623-627